Trial *
Publication Dengiz E, Med Gas Res, 2021 (published paper)
Dates: 2020-08-01 to 2020-09-30
Funding: Private (Edis Pharma Pharmaceutical İndustry)
Conflict of interest: Yes

Methods
RCT
Location : Single center / Turkey
Follow-up duration (days): 5
Inclusion criteriapositive PCR test; between the ages of 18–80 years.
Exclusion criteriaglucose-6-phosphate dehydrogenase deficiency (favizm allergy); previous lung cancer or suspected lung mass in lung tomography; previous surgery in their lungs; patients who did not complete treatment.
Interventions
Treatment
Oxygen-Ozone
0.2 parts per million/second ozone gas passed through olive oil applied 3 times a day for 10 minutes at intervals of 5 minutes for 5 days
Control
Standard care ( / )
Definition of Standard care: Hydroxycholoroquine: 2× 200 mg tablets, oral, for 5 days; Favipiravir: Loadıng: 2× 1600 mg tablets, oral, for 1 day - Maıntenance: 2× 600 mg tablets, oral, for 4 days.
Participants
Randomized
30 participants (n1=15 / n2= 15)
Characteristics of participants
N=30
Mean age : NR
17 males
Severity : Mild: n=* / Moderate: n=*/ Severe: n=* Critical: n=*
Primary outcome
In the register
NR
In the report
NR
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the published article was used in data extraction and risk of bias assessment. No protocol or study registry were available. There was no information on randomization process, sample size calculations or if outcomes were determined a priori.